株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

全身性エリテマトーデス (SLE) 治療薬のパイプライン動向

Systemic Lupus Erythematosus: Programs Targeting Cytokine and Growth Factor Signaling Dominate First-in-Class Pipeline

発行 GlobalData 商品コード 907771
出版日 ページ情報 英文 53 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
全身性エリテマトーデス (SLE) 治療薬のパイプライン動向 Systemic Lupus Erythematosus: Programs Targeting Cytokine and Growth Factor Signaling Dominate First-in-Class Pipeline
出版日: 2019年06月26日 ページ情報: 英文 53 Pages
概要

当レポートでは、全身性エリテマトーデス (SLE) 治療薬の治験・上市動向について分析し、治験段階別および標的分子別の製品数の推移や、ファーストインクラス製品が占める比率、主要企業の製品開発・上市動向、といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 全身性エリテマトーデス (SLE):エグゼクティブ・サマリー

第3章 イントロダクション

第4章 疾患概要

  • 病因と病態生理
  • 分類方法/病期分類システム
  • SLE関連の現在停止中の製品開発
  • SLEの疫学
  • 上市済み製品の概要

第5章 パイプライン製品のイノベーションの評価

  • 概要
  • パイプライン製品:開発段階別・分子の種類別
  • パイプライン製品:標的分子別
  • 製品数の比較分析:上市済み製品とパイプライン製品、治療標的の分類別
  • 製品数の比較分析:ファーストインクラスとそれ以外、標的分子の種類別
  • ファーストインクラス製品とファーストインクラス標的分子の比率:パイプライン製品の場合

第6章 ファーストインクラス標的分子の評価

  • 概要
  • パイプライン計画:NTK (非受容体型チロシンキナーゼ) を標的とするもの
  • パイプライン計画:補体C3 (第3成分) を標的とするもの
  • パイプライン計画:cGAS (cGMP-AMPシンターゼ) を標的とするもの
  • パイプライン計画:インターロイキン2受容体サブユニットβを標的とするもの
  • パイプライン計画:インターロイキン1関連キナーゼ1を標的とするもの
  • パイプライン計画:マンナン結合レクチンセリンプロテアーゼ2を標的とするもの
  • パイプライン計画:Toll様受容体8を標的とするもの

第7章 主要企業と資本取引動向

  • 概要

第8章 付録

図表

List of Tables

  • Table 1: SLE Criteria
  • Table 2: SLE Diagnosed Prevalent Cases, millions (N), 2015-2025

List of Figures

  • Figure 1: Overview of the Etiology and Pathogenesis of SLE
  • Figure 2: Integrated Hypothesis for the Pathogenesis of SLE
  • Figure 3: SLE, Global Market by Molecule Type and Molecular Target, 2019
  • Figure 4: SLE, Global, Pipeline by Stage of
目次
Product Code: GDHC495FP

The Systemic Lupus Erythematosus (SLE) pipeline is characterized by a high level of first-in-class innovation when compared to other therapy areas and the industry as a whole. Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While Systemic Lupus Erythematosus (SLE) can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN).

The high level of first-in-class innovation translates to numerous promising first-in-class targets with strong therapeutic potential. Of the total products in the Systemic Lupus Erythematosus (SLE) pipeline, 43% are first-in-class, indicating a high level of innovation.

There are currently 146 products in active development for Systemic Lupus Erythematosus (SLE). Around half of the pipelines are in early stage development, with 74 products in the discovery and preclinical stages. There are 50 first-in-class programs in the pipeline, acting on 48 first-in-class molecular targets.

Mark Needham, Pharma Analyst, says: "We have assessed all first-in-class molecular targets in the Systemic Lupus Erythematosus (SLE) pipeline and ranked them based on the commercial potential. We found non receptor tyrosine protein kinase, also known as tyrosine kinase 2 (TYK2) to have the highest potential. TYK2 is a key component of the IFN-1 signaling pathway, which is increasingly recognized as a central pathogenic mediator in Systemic Lupus Erythematosus (SLE). Other first-in-class targets with strong therapeutic potential include those targeting the complement system and adaptive signaling."

Needham adds: "Programs targeting cell surface antigens are prominent, comprising 12% of the pipeline. The remainder is made up of smaller target families, such as complement/adaptive immunity, neurotransmitters and receptors, and hormones and receptors."

The recent report "Systemic Lupus Erythematosus: Programs Targeting Cytokine and Growth Factor Signaling Dominate First-in-Class Pipeline", helps in understanding the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology. It also helps in visualizing the composition of the Systemic Lupus Erythematosus (SLE) market in terms of dominant molecule types and molecular targets.

Scope:

  • There are 146 pipeline programs in active development for SLE. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class?
  • Which molecular target classes are prominently represented in the first-in-class SLE pipeline? Which first-in-class targets have been identified as most promising for the treatment of SLE? How does the distribution of target classes differ in terms of development stage?
  • Across the SLE landscape, there are 112 active companies. Which companies have formed partnerships? Which companies have first-in-class assets in development with no prior deal involvement?

Reasons to buy:

  • Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology. Visualize the composition of the SLE market in terms of dominant molecule types and molecular targets.
  • Analyze and compare the SLE pipeline and stratify by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to their clinical potential. Promising first-in-class targets have been reviewed in greater detail.
  • Recognize commercial opportunities by identifying first-in-class pipeline products for SLE that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class SLE products.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. SLE: Executive Summary

  • 2.1. Pipeline Holds Potential for the Approval of More Targeted Therapies
  • 2.2. High Levels of First-in-Class Innovation
  • 2.3. High Unmet Need Remains for Disease-Modifying Pharmacotherapies

3. Introduction

  • 3.1. Catalyst
  • 3.2. Related Reports
  • 3.3. Upcoming Related Reports

4. Disease Overview

  • 4.1. Etiology and Pathophysiology
  • 4.2. Classification or Staging Systems
  • 4.3. Sustained Innovation in SLE
  • 4.4. Epidemiology for SLE
  • 4.5. Overview for Marketed Products

5. Assessment of Pipeline Product Innovation

  • 5.1. Overview
  • 5.2. Pipeline by Stage of Development and Molecule Type
  • 5.3. Pipeline by Molecular Target
  • 5.4. Comparative Distribution of Programs Between SLE Market and Pipeline by Therapeutic Target Family
  • 5.5. Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
  • 5.6. Ratio of First-in-Class Programs to First-in-Class Molecular Targets Within the Pipeline

6. First-in-Class Molecular Target Evaluation

  • 6.1. Overview
  • 6.2. Pipeline Programs Targeting Non Receptor Tyrosine Protein Kinase
  • 6.3. Pipeline Programs Targeting Complement C3
  • 6.4. Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5
  • 6.5. Pipeline Programs Targeting Cyclic GMP-AMP Synthase
  • 6.6. Pipeline Programs Targeting Interleukin 2 Receptor Subunit Beta
  • 6.7. Pipeline Programs Targeting Interleukin 1 Receptor Associated Kinase 1
  • 6.8. Pipeline Programs Targeting Mannan-Binding Lectin Serine Protease 2
  • 6.9. Pipeline Programs Targeting Toll-Like Receptor 8

7. Key Players and Deals

  • 7.1. Overview

8. Appendix

  • 8.1. Bibliography
  • 8.2. Abbreviations
  • 8.3. Methodology
  • 8.4. About the Authors
  • 8.5. About GlobalData
  • 8.6. Contact Us
  • 8.7. Disclaimer
Back to Top